Use of systemic therapies at the end of life in cancer patients: has anything changed over the last decade? A multicenter retrospective study
Palliative Medicine in Practice · 30.01.2026 · 20
DOI: 10.5603/pmp.115187 ↗Kurz gefasst
Fachartikel in der Zeitschrift Palliative Medicine in Practice, online erschienen am 30.01.2026. Verfasst von Henrik Schulte-Hürmann und 4 weiteren Autor:innen.
Themen: Onkologische Pflege, Palliativpflege
Abstract (Originalsprache)
BACKGROUND: Discontinuing systemic therapy poses a significant challenge in the continuation of care of cancer patients. Current evidence indicates that disadvantages associated with systemic therapies at the end of life outweigh their benefits. Those include continued treatment-related toxicity and thus an impact on quality of life, increased psychological burden, potentially delayed access to dedicated palliative care, treatment burden, and more frequent hospitalizations. The American Society of Clinical Oncology considers the administration of systemic therapy within the last 14 days of life to be a negative quality indicator, while the European Society for Medical Oncology recommends against the administration of chemotherapy or immunotherapy within the final 30 days of life. METHODS: We analyzed whether contemporary evidence has led to a more restrictive use of systemic therapies at the end of life. We performed a retrospective, multicenter study including 1,500 patients who died on palliative care wards due to oncological diseases. RESULTS: Seventy-two percent of treated patients had received systemic treatment within the last 3 months of life, 47% within the last 30 days, and 20% within the last 14 days before death. Older patients received systemic therapy significantly less often. In the final month of life, patients were treated with immunotherapy twice as often as with (cytotoxic) chemotherapy. CONCLUSIONS: Systemic therapies are not administered more restrictively despite accumulating evidence. Contributing factors include clinicians’ and patients’ tendencies to overestimate remaining life expectancy and to view treatment efficacy overly optimistically. Earlier integration of palliative care and intensified interdisciplinary collaboration could lead to improvements.
Zitieren
APA
Schulte-Hürmann, H., Arnold, D., Faust, M., Weilert, H., & Schilling, G. (2026). Use of systemic therapies at the end of life in cancer patients: has anything changed over the last decade? A multicenter retrospective study. Palliative Medicine in Practice, 20(0). https://doi.org/10.5603/pmp.115187
Vancouver
Schulte-Hürmann H, Arnold D, Faust M, Weilert H, Schilling G. Use of systemic therapies at the end of life in cancer patients: has anything changed over the last decade? A multicenter retrospective study. Palliative Medicine in Practice. 2026;20(0). doi:10.5603/pmp.115187
BibTeX
@article{SchulteHrmann2026,
author = {Schulte-Hürmann, Henrik and Arnold, Dirk and Faust, Markus and Weilert, Hauke and Schilling, Georgia},
title = {Use of systemic therapies at the end of life in cancer patients: has anything changed over the last decade? A multicenter retrospective study},
journal = {Palliative Medicine in Practice},
year = {2026},
volume = {20},
number = {0},
doi = {10.5603/pmp.115187}
}
EUVIMED